InteRNA Technologies

OverviewSuggest Edit

InteRNA Technologies is a biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer. It uses its microRNA (miRNA) discovery and functional validation platform to develop a drug candidate for treatment of patients with hepatocellular carcinoma, melanoma, triple-negative breast cancer, and lung cancer.
TypePrivate
Founded2006
HQNijmegen, NL
Websiteinterna-technologies.com

Latest Updates

Employees (est.) (Jul 2022)26(+4%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at InteRNA Technologies

Michel Janicot

Michel Janicot

Acting Chief Development Officer
Roel Schaapveld

Roel Schaapveld

Chief Executive Officer
Laurens van Pinxteren

Laurens van Pinxteren

Chief Operating Officer
Show more

InteRNA Technologies Office Locations

InteRNA Technologies has an office in Nijmegen
Nijmegen, NL (HQ)
Jonkerbosplein 52
Show all (1)

InteRNA Technologies Financials and Metrics

Summary Metrics

Founding Date

2006

InteRNA Technologies total Funding

$22.3 m

InteRNA Technologies latest funding size

$9.98 m

Time since last funding

2 years ago

InteRNA Technologies investors

InteRNA Technologies's latest funding round in February 2021 was reported to be $10 m. In total, InteRNA Technologies has raised $22.3 m
Show all financial metrics

InteRNA Technologies Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

InteRNA Technologies Online and Social Media Presence

Embed Graph

InteRNA Technologies Blogs

InteRNA Technologies Announces U.S. FDA Clearance of IND Application for Phase I Clinical Trial with Lead microRNA Candidate INT-1B3

-- IND approval enables clinical trial advancement and enrollment of dose expansion cohorts in the US -- Utrecht, The Netherlands, December 2, 2021 – InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today it recei…

InteRNA Technologies Establishes Clinical Advisory Board and Appoints New Members to Scientific Advisory Board

-- Adding deep preclinical and clinical immuno-oncology expertise to expand InteRNA’s preclinical pipeline and accelerate clinical-stage lead candidate INT-1B3 -- Utrecht, The Netherlands, October 19, 2021 – InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based the…

InteRNA Appoints Established Oncology Innovator Andrea van Elsas, PhD, to its Supervisory Board

Utrecht, The Netherlands, October 12, 2021 – InteRNA Technologies, a clinical-stage biotech company developing microRNA (miRNA)-based therapeutics with a focus on cancer, announced today the appointment of Andrea van Elsas, PhD, as a new member of the Company’s Supervisory Board. Dr. van Elsas trans…

GBR Connect Series – Interview with Roel Schaapveld, InteRNA Technologies – US Pharma & Biopharma

Click here to read the interview with our CEO Roel Schaapveld in Global Business Report. The post GBR Connect Series – Interview with Roel Schaapveld, InteRNA Technologies – US Pharma & Biopharma appeared first on InteRNA Technologies.

Vacancy Research Scientist

InteRNA Technologies – a clinical-stage biotechnology company based in Utrecht (The Netherlands) – is currently seeking a talented and highly motivated Research Scientist to join the company’s Research and Development group.InteRNA focuses on the discovery and development of RNA therapeutics (microR…

InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous

Nice read on the renewed interest in RNA (e.g. mRNA, gRNA, siRNA, saRNA, miRNA, antisense) -based therapeutics! Getting more and more an established drug class. Click here to read more Het bericht InteRNA and the renewed interest in RNA therapeutics in the March 2021 edition of MedNous verscheen eer…

InteRNA Technologies Frequently Asked Questions

  • When was InteRNA Technologies founded?

    InteRNA Technologies was founded in 2006.

  • Who are InteRNA Technologies key executives?

    InteRNA Technologies's key executives are Michel Janicot, Roel Schaapveld and Laurens van Pinxteren.

  • How many employees does InteRNA Technologies have?

    InteRNA Technologies has 26 employees.

  • Who are InteRNA Technologies competitors?

    Competitors of InteRNA Technologies include SK Biopharmaceuticals, AltruBio and Deciphera Pharmaceuticals.

  • Where is InteRNA Technologies headquarters?

    InteRNA Technologies headquarters is located at Jonkerbosplein 52, Nijmegen.

  • Where are InteRNA Technologies offices?

    InteRNA Technologies has an office in Nijmegen.

  • How many offices does InteRNA Technologies have?

    InteRNA Technologies has 1 office.